Results 91 to 100 of about 26,161 (209)

The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCC

Nature Communications
HIV-1 envelope glycoproteins (Env) from primary HIV-1 isolates typically adopt a pretriggered “closed” conformation that resists to CD4-induced (CD4i) non-neutralizing antibodies (nnAbs) mediating antibody-dependent cellular cytotoxicity (ADCC).
Jonathan Richard, Michael W. Grunst, Ling Niu, Marco A. Díaz-Salinas, Li Zhu, William D. Tolbert, Lorie Marchitto, Fei Zhou, Catherine Bourassa, Hongil Kim, Sri Lakshmi Tejaswi Boodapati, Derek Yang, Ta Jung Chiu, Hung-Ching Chen, Mehdi Benlarbi, Guillaume Beaudoin-Bussières, Suneetha Gottumukkala, Wenwei Li, Katrina Dionne, Étienne Bélanger, Debashree Chatterjee, Halima Medjahed, Wayne A. Hendrickson, Joseph Sodroski, Zabrina C. Lang, Abraham J. Morton, Rick K. Huang, Doreen Matthies, Amos B. Smith, Priti Kumar, Walther Mothes, James B. Munro, Marzena Pazgier, Andrés Finzi   +33 more
doaj   +1 more source

Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post‐Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight

Immunity, Inflammation and Disease, Volume 14, Issue 8, August 2026.
ABSTRACT Background Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may rarely coexist with malignancies such as lung cancer. Case Presentation This case report presents the first documented use of ofatumumab, a fully human anti‐CD20 monoclonal antibody, in a 75‐year‐old female with acetylcholine receptor (AChR)‐antibody‐positive ...
Xia Long, Yanwen Xu, Juan Xiong, Wenfeng Peng, Jinhua Qiu, Yanxia Zhou   +5 more
wiley   +1 more source

Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell‐Activating Properties in B Cell Lymphoma

Journal of Extracellular Vesicles, Volume 15, Issue 8, August 2026.
B cell lymphoma‐derived EVs are intrinsically neutral or suppressive with respect to NK cell activity (panel 1). In the context of rituximab treatment, NK cytotoxicity is enhanced by antibody‐dependent cell‐mediated cytotoxicity (panel 2). Herein we show that, in addition, rituximab recognition of EV‐associated CD20 generates immune complexes that ...
Adrián V. Otero, Paula Soledad Pérez, Belen Gaete‐Ramírez, Gregorio Cordini, Matías Norte, Enriqueta Martínez, Nicolás Marsol, Cecilia Malusardi, Sofía Rivarola, Ana Cantillo, María Luz Leicaj, Constanza Russo, Juan Quarroz Braghini, Federico Penas, Glenda Ernst, Cecilia Cabral, Silvina Palmer, Manuel Varas‐Godoy, Lourdes Arruvito, Matías Ostrowski   +19 more
wiley   +1 more source

Quantum‐Capacitance Biosensing Enables Real‐Time Monitoring of Naxitamab for Therapeutic Response Stratification in Neuroblastoma

Small Science, Volume 6, Issue 8, August 2026.
Quantum‐capacitance biosensing enables real‐time monitoring of naxitamab in patient samples via laser‐fabricated electrodes and single‐point calibration. The proposed platform provides rapid and sensitive quantification, with the potential to enable therapeutic drug monitoring and patient stratification according to circulating naxitamab levels, while ...
Andy Bruno, Ruslán Alvarez‐Diduk, Paula Lara, Gabriel Maroli, Cristina Larrosa, Sandra López‐Miralles, Jaume Mora, Carlos J. Rodríguez‐Hernández, Arben Merkoçi   +8 more
wiley   +1 more source

TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC

Thoracic Cancer, Volume 17, Issue 16, August 2026.
TLS in lung cancer adjuvant therapy: (A) cellular composition (T/B cells, DCs); (B) mechanistic pathways (antigen presentation, GC‐like B responses, TRM maintenance); (C) clinical evaluation (IHC, digital pathology, spatial transcriptomics); (D) future directions (dynamic monitoring, intercellular interactions, multicenter trials, clinical translation).
Zhiqi Li, Lina Zhang, Yujie Dong, Ling Yi, Weiying Li, Jinghui Wang, Yuanming Pan   +6 more
wiley   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, Volume 81, Issue 8, Page 2775-2791, August 2026.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

A cDC1‐NK/T‐Malignant Cell Circuit Drives Immunogenic Remodeling Under PD‐1 Blockade in Gastric Cancer

Cancer Science, Volume 117, Issue 8, Page 2098-2114, August 2026.
Chemotherapy combined with nivolumab reshapes the gastric cancer tumor microenvironment (TME) and is accompanied by an enrichment of reduced cytotoxicity NK (RC‐NK) cells. Rather than acting as classical cytotoxic effectors, these RC‐NK cells appear to shape the TME by promoting an immunostimulatory circuit that engages adaptive immunity.
Takuya Nakatsuru, Hiroki Yamashita, Chiaki Mashima, Guoqiang Zhang, Hitoshi Saito, Tatsunori Minamide, Keita H. Nagaoka, Ryo Kamata, Shunsuke A. Sakai, Gaku Yamamoto, Tomoko Y. Morita, Kazuki Nakai, Yumi Hakozaki, Kumi Kinoshita, Yui Takahashi, Izuma Nakayama, Akihito Kawazoe, Yuko Ishii, Sai M. Pulukuri, Hiroshi Haeno, Yukie Kashima, Kohei Shitara, Tomonori Yano, Takeshi Saito, Akihiro Ohashi   +24 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, Volume 117, Issue 2, Page 305-319, August 2026.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Counteracting Influenza Virus Evolution Through the Full Spectrum of Broadly Protective Antibodies

Immunological Reviews, Volume 341, Issue 1, August 2026.
ABSTRACT Despite the presence of licensed vaccines and therapeutics, influenza viruses remain a major public health concern, as they cause seasonal respiratory infections and pose a pandemic threat through the emergence of zoonotic strains. Although neutralizing antibodies elicited by seasonal vaccination constitute a primary defense against infection,
Yu Adachi, Yoshimasa Takahashi
wiley   +1 more source

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source